CCDC6, a gene product in fusion with different protoncogenes, as a potential chemotherapeutic target.

CCDC6, a gene product in fusion with different protoncogenes, as a potential chemotherapeutic target. Cancer Biomark. 2019 Mar 15;: Authors: Laxmi A, Gupta P, Gupta J Abstract Cancer, a deadly disease is characterized by abnormal cell growth with the potential to invade to other parts of the body. Most cancers start due to changes at gene level that happen over a person's lifetime when DNA repair system becomes faulty. CCDC6, one of the players in DNA repair system acts as a tumor suppressor gene. It was originally identified in chimeric genes caused by chromosomal translocation involving RET proto-oncogene in some thyroid tumors. Different fusion chimers with different proto-oncogenes like RET are known for CCDC6 which hampered its function. Further, CCDC6 is recognized as a pro-apoptotic phosphoprotein, which is an ATM substrate responsive to genotoxic stress. In this article, we reviewed the published literature to characterize CCDC6 fusions with proto-oncogenes and the role of natural phytochemicals which can potentially alter CCDC6 activity and thus can prove beneficial for cancer patients. PMID: 30909182 [PubMed - as supplied by publisher]
Source: Cancer Biomarkers : Section A of Disease Markers - Category: Cancer & Oncology Authors: Tags: Cancer Biomark Source Type: research